1. In-Hospital Mortality Risk Factor Analysis in Multivessel Percutaneous Coronary Intervention Inpatient Recipients in the United States
- Author
-
Ravi Tummala, Asma T Khan, Keerthika Mathialagan, Suchi D Shah, Swathi P Kavuri, Gagan Kaur, Ramneek K Sandhu, Temitope Ajibawo, and Era Rawal
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Mortality rate ,Confounding ,Cardiology ,primary pci ,General Engineering ,acute myocardial infarction ,Percutaneous coronary intervention ,Odds ratio ,primary percutaneous coronary intervention (pci) ,medicine.disease ,Logistic regression ,Quality Improvement ,Respiratory failure ,Internal medicine ,nationwide inpatient sample (nis) ,Internal Medicine ,Medicine ,perioperative mortality ,Myocardial infarction ,Risk factor ,business ,in-hospital mortality - Abstract
Objectives The primary goal of our study is to evaluate the mortality rate in inpatient recipients of multivessel percutaneous coronary intervention (MVPCI) and to evaluate the demographic risk factors and medical complications that increase the risk of in-hospital mortality. Methods We conducted a cross-sectional study using the Nationwide Inpatient Sample (NIS, 2016) and included 127,145 inpatients who received MVPCI as a primary procedure in United States' hospitals. We used a multivariable logistic regression model adjusted for demographic confounders to measure the odds ratio (OR) of association of medical complications and in-hospital mortality risk in MVPCI recipients. Results The in-hospital mortality rate was 2% in MVPCI recipients and was seen majorly in older-age adults (>64 years, 74%) and males (61%). Even though the prevalence of mortality among females was comparatively low, yet in the regression model, they were at a higher risk for in-hospital mortality than males (OR 1.2; 95% CI 1.13-1.37). While comparing ethnicities, in-hospital mortality was prevalent in whites (79%) followed by blacks (9%) and Hispanics (7.5%). Patients who developed cardiogenic shock were at higher odds of in-hospital mortality (OR 9.2; 95% CI 8.27-10.24) followed by respiratory failure (OR 5.9; 95% CI 5.39-6.64) and ventricular fibrillation (OR 3.5; 95% CI 3.18-3.92). Conclusion Accelerated use of MVPCI made it important to study in-hospital mortality risk factors allowing us to devise strategies to improve the utilization and improve the quality of life of these at-risk patients. Despite its effectiveness and comparatively lower mortality profile, aggressive usage of MVPCI is restricted due to the periprocedural complications and morbidity profile of the patients.
- Published
- 2021
- Full Text
- View/download PDF